{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-093244","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-08-25T11:30:33+00:00","discovered_at":"2026-08-25T11:35:13.364143+00:00","generated_at":"2026-08-25T11:35:18.489573+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Incannex doses first patient in DReAMzz Phase 2 study of IHL-42X for sleep apnea","bullets":["First patient dosed in DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea (OSA).","All 14 U.S. clinical trial sites have IRB approval; drug product manufactured and patient screening underway.","Builds on Phase 2 RePOSA results: statistically significant AHI reductions vs placebo, individual reductions up to 83%.","FDA granted Fast Track designation to IHL-42X program, supporting expedited development and review.","Study aims to optimize dose selection and inform design of planned Phase 3 development program."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-093244","json":"https://secwatch.observer/filing/0001213900-26-093244.json","markdown":"https://secwatch.observer/filing/0001213900-26-093244.md","text":"https://secwatch.observer/filing/0001213900-26-093244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/0001213900-26-093244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026093244/ea0303140-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-25T11:35:18.489573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}